Notes on Pharming Group, N.V. <a href='read_msg.asp?message_id=25275659'>#msg-25275659</a> EMEA rejects Rhucin for HAE <a href='read_msg.asp?message_id=17760532'>#msg-17760532</a> Musings by ‘rustyboy’ (precedes Rhucin news above) <a href='read_msg.asp?message_id=20830051'>#msg-20830051</a> Pipeline overview <a href='read_msg.asp?message_id=22208171'>#msg-22208171</a> Phase-3 Rhucin data <a href='read_msg.asp?message_id=22482530'>#msg-22482530</a> Pharming seeks US partner <a href='read_msg.asp?message_id=18949245'>#msg-18949245</a> IP cross-license with GTC